TY - JOUR
T1 - Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy
T2 - A study of three cohorts
AU - Dyck, Peter J.
AU - Dyck, P. James B.
AU - Velosa, Jorge A.
AU - Larson, Timothy S.
AU - O'Brien, Peter C.
PY - 2000
Y1 - 2000
N2 - OBJECTIVE - To test quantitative sensation testing (QST) patterns of hypoesthesia and hyperalgesia as indicators of diabetic polyneuropathy (DPN) and its severity. RESEARCH DESIGN AND METHODS - We used Computer-Assisted Sensory Examination IV: characterized the QST results of the foot of each patient in three diabetic cohorts (~1,500 patients) as hyperesthetic (≤2.5th percentile), low-normal (2.5th-50th percentiles), high-normal (50th- 97.5th percentiles), or hypoesthetic (≥97.5th percentile); and tested associations with symptoms, impairments, and test abnormalities. RESULTS - Overall neuropathic impairment was most severe in the pancreas-renal transplant and nerve growth factor cohorts, but it was much less severe in the population-based Rochester Diabetic Neuropathy Study (RDNS) cohort. The frequency distribution of sensory abnormalities mirrored this difference. When the QST spectra of diabetic cohorts were compared with those of the control subject cohort for vibration and cooling sensations, the only abnormality observed was hypoesthesia, which was expressed as an increased number of subjects with values at or above the 97.5th percentile or by an increased percentage of cases with high-normal values. Symptoms and impairments of DPN were significantly more frequent in the subjects with values at or above the 97.5th percentile than in the subjects whose values were between the 50th and 97.5th percentiles. For heat pain (HP) sensation thresholds (intermediate pain severity [HP:5], pain threshold [HP:0.5], and pain-stimulus response slope [HP:5-0.5]), an increased frequency of both hypoalgesia and hyperalgesia was observed (especially in the RDNS cohort). Steeper pain-stimulus response slopes were significantly associated with sensory symptoms, including severity of pain.
AB - OBJECTIVE - To test quantitative sensation testing (QST) patterns of hypoesthesia and hyperalgesia as indicators of diabetic polyneuropathy (DPN) and its severity. RESEARCH DESIGN AND METHODS - We used Computer-Assisted Sensory Examination IV: characterized the QST results of the foot of each patient in three diabetic cohorts (~1,500 patients) as hyperesthetic (≤2.5th percentile), low-normal (2.5th-50th percentiles), high-normal (50th- 97.5th percentiles), or hypoesthetic (≥97.5th percentile); and tested associations with symptoms, impairments, and test abnormalities. RESULTS - Overall neuropathic impairment was most severe in the pancreas-renal transplant and nerve growth factor cohorts, but it was much less severe in the population-based Rochester Diabetic Neuropathy Study (RDNS) cohort. The frequency distribution of sensory abnormalities mirrored this difference. When the QST spectra of diabetic cohorts were compared with those of the control subject cohort for vibration and cooling sensations, the only abnormality observed was hypoesthesia, which was expressed as an increased number of subjects with values at or above the 97.5th percentile or by an increased percentage of cases with high-normal values. Symptoms and impairments of DPN were significantly more frequent in the subjects with values at or above the 97.5th percentile than in the subjects whose values were between the 50th and 97.5th percentiles. For heat pain (HP) sensation thresholds (intermediate pain severity [HP:5], pain threshold [HP:0.5], and pain-stimulus response slope [HP:5-0.5]), an increased frequency of both hypoalgesia and hyperalgesia was observed (especially in the RDNS cohort). Steeper pain-stimulus response slopes were significantly associated with sensory symptoms, including severity of pain.
UR - http://www.scopus.com/inward/record.url?scp=0034079572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034079572&partnerID=8YFLogxK
U2 - 10.2337/diacare.23.4.510
DO - 10.2337/diacare.23.4.510
M3 - Article
C2 - 10857944
AN - SCOPUS:0034079572
SN - 0149-5992
VL - 23
SP - 510
EP - 517
JO - Diabetes care
JF - Diabetes care
IS - 4
ER -